About the Book
At a time when the field of cardiac safety is going through important changes, this unique book provides the rationale for, and cutting-edge explanations of, new regulatory landscapes that will likely govern cardiac safety assessments globally for the foreseeable future. Exposure-response modeling is already being accepted by regulatory agencies in lieu of the traditional Thorough QT/QTc Study, and the Comprehensive in vitro Proarrhythmia Assay initiative is well under way.
Developments in the field of cardiovascular safety are also described and discussed in the book. These include the search for more efficient ways to exonerate new drugs for type 2 diabetes from an unacceptable cardiovascular liability, how best to address off-target blood pressure increases induced by noncardiovascular drugs, and the continued evolution of the discipline of Cardio-oncology.
“a resource that will likely serve as a standard for years to come”
- Dr Jonathan Seltzer
Therapeutic Innovation & Regulatory Science, 2017;51(2):180
“I have no hesitation in recommending this book as a valuable reference source”
- Dr Rashmi Shah
Journal for Clinical Studies, 2017;9(1):62-63
Table of Contents:
The Central Importance of Cardiovascular Safety in Contemporary New Drug Development.- The Biological Basis of Drug Responses.- Cardiovascular Structure, Function, Pathophysiology, & Disease.- The Current Regulatory Landscape.- The "Comprehensive In Vitro Proarrhythmia Assay" Initiative.- The "Early ECG Assessment" Initiative.- The "Submission of Extended Digital ECG Data" Initiative.- Meta-analysis and Meta-methodology.- Current Regulatory Landscapes and their Potential Evolution.- Off-target Blood Pressure Responses to Non-cardiovascular Drugs.- Oncology Drug Development and Therapeutics: Cardiotoxicity Considerations.- Postmarketing Surveillance.- Regulatory Perspectives on General Drug Safety.- Future Directions in Cardiovascular Safety.- References.
About the Author :
J. Rick Turner, BSc (Hons), PGCE, PhD, DSc, is an experimental research scientist, clinical trialist, author, editor, and educator. He spent the first part of his professional career in the field of Cardiovascular Behavioral Medicine, detailing the individual differences apparent in cardiovascular responses to behavioral and psychological stressors, including genetic influences upon them. He received two international awards for his research, and is Co-Editor of the 2013 Springer volume Encyclopedia of Behavioral Medicine, the definitive work in this area.
Dr Turner is currently Chief Scientific Advisor, Cardiac Safety Services, and Senior Scientific Director, Clinical Communications, Quintiles. He is also member of Quintiles’ Cardiovascular and Diabetes Centers of Excellence. He is the author and co-author of over 120 publications in peer-reviewed journals, and the author, co-author,and editor of 15 books. Additionally, he holds the positions of Adjunct Professor of Pharmacy Practice, Campbell University College of Pharmacy & Health Sciences, and President and Chief Scientific Officer, Turner Medical Communications.
Dilip R. Karnad, MD, FACP, FRCP (Glasg), is an internist and an expert in cardiac safety with extensive clinical, research and teaching experience. He is currently Head of the Research Team, Cardiac Safety Services, Quintiles. He has a particular interest in statistical approaches to cardiac safety assessments, and has published over 20 papers in this field. He is a Fellow of the American College of Physicians and a Fellow of the Royal College of Physicians (of Glasgow), and also a practicing internist and critical care physician affiliated to Jupiter Hospital, Thane.
Snehal Kothari, MD, DM, FACC, FESC is a cardiologist and an expert in cardiac safety with extensive clinical, research and teaching experience. He is currently Chief Medical & Scientific Officer of theCore ECG Laboratory, Cardiac Safety Services, and Global Head of the Cardiac Safety Centre of Excellence, Quintiles. He is also a practicing Interventional Cardiologist affiliated to Lilavati Hospital & Research Centre, Mumbai. He is the recipient of over 30 awards and honors, and is a Fellow of the American College of Cardiology, the European Society of Cardiology, and the Asian Pacific Society of Cardiology. He has over 80 peer-reviewed publications and published abstracts.
Review :
“Dr Turner and his colleagues have done the drug development community a service by providing a compendium of cardiovascular safety. They have done a masterful job of placing cardiovascular safety firmly within the context of overall drug development. As such, Cardiovascular Safety in Drug Development and Therapeutic Use is a book that should be on the shelf of every drug developer.” (Jonathan H. Seltzer, Therapeutic Innovation Regulatory Science, Vol. 51 (2), March, 2017)
“This book brings together a wealth of information … state-of-the-art knowledge on the mechanisms involved in drug-induced adverse cardiovascular effects and the investigational strategies available to characterise drugs for these effects. … The authors deserve our congratulations for their immense efforts and well-presented contribution to the scientific community. … It caters for all professionals interested in cardiovascular safety of drugs, including academic, regulatory and pharmaceutical scientists. I have no hesitation in recommending this book as a valuable reference source.” (Dr. Rashmi Shah, Journal for Clinical Studies, Vol. 9 (1), 2017)
“The aim is to provide researchers and clinicians fundamental knowledge in the field of biopharmaceutical cardiovascular safety in a comprehensive manner. This book is written for readers at all levels of involvement with drug development and therapeutic use, from pharmaceutical researchers to pharmacists and physicians. … Impressive features of the book include the extensive references and further reading lists at the end of each chapter … .” (John C. Gulotta, Doody's Book Reviews, November, 2016)
